RxDoctor Payments Data

Marlene Blaise, MD

Cardiovascular Disease · Alpharetta, GANPI 1477587822

Payments from drug & device makers

$397in general payments, 2019–2025

Across 21 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$107
  • Kiniksa Pharmaceuticals, Ltd.$56
  • Baxter Healthcare$52
  • Kiniksa Pharmaceuticals International, PLC$32
  • Novartis$26
  • AstraZeneca$26
  • plus $98 from 6 others

What the payments were for

  • Food & beverage$397100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$397 in reported general payments places this provider in the 20th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$154,447
Medicare patients
351
Services billed
1,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$302,110
JardianceEmpagliflozin82$102,363
FarxigaDapagliflozin Propanediol91$64,971
Repatha SureclickEvolocumab46$61,499
XareltoRivaroxaban41$47,029
WegovySemaglutide28$44,383
EntrestoSacubitril/Valsartan14$27,059
Praluent PenAlirocumab26$23,092
OzempicSemaglutide18$20,374
VascepaIcosapent Ethyl19$18,473
Ezetimibe178$7,288
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide93$6,978
Metoprolol Succinate578$6,610
Dabigatran EtexilateDabigatran Etexilate Mesylate16$5,815
ZypitamagPitavastatin Magnesium12$2,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$102,36382 claims
AstraZenecaFarxiga$26$64,97191 claims
Novo NordiskWegovy, Ozempic$107$64,75746 claims
NovartisEntresto$26$27,05914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →